三种肿瘤标志物CYFRA21-1、CA125与CEA联合检测对于非小细胞肺癌的表达规律及其临床应用价值

目的探讨联合检测CYFRA21-1、CA125、CEA对非小细胞肺癌的临床应用价值。方法研究对象为我院2004年6月至2008年6月由病理证实的非小细胞肺癌患者165例,测定其血清CYFRA21-1、CA125、CEA值。结果CYFRA21-1在鳞癌中阳性率最高为54．55％（30／55）;CA125、CEA在腺癌中阳性率最高,分别为58．59％（58／99）、52．53％（52／99）。三项联合检测总阳性率明显升高为81．82％（135／165）,其中Ⅲ期和Ⅳ期非小细胞肺癌的阳性检出率分别为89．13％（41／46）、86．52％（77／89）,均高于I期和Ⅱ期的阳性检出率。结论联合检测CYFRA21-1、CA125和CEA可起到互补作用,从而明显提高非小细胞肺癌的阳性检出率,且肿瘤的阳性检出率随病情的进展而升高。

Total positive rate of CYFRA21-1, CA125 and CEA: significance in expression and diagnosis of non-small cell lung cancer

Objective To investigate the clinical significance of combined detection of CYFRA21-1, CA125 and CEA in non-small cell lung cancer(NSCLC). Methods One hundred and sixty-five patients with pathologically proven NSCLC as the subjects were analyzed by measuring the levels of above three markers in serum in the period from June 2004 to June 2008. Results The highest positive rate of CYFRA21-1, 54.55% (30/55) was found in the patients with squamous carcinoma, while the positive rate of CA125 and CEA in adenocarcinoma was 58. 5% (58/99) and 52. 53% (52/99) ,respectively, each was higher than that of CYFRA21-1. The total positive rate was 81. 82% (135/165) , obviously higher than that of any single marker. The total rates of positive findings of NSCLC in stages III and IV were 89. 13% (41/46) and 86. 52 (77/89) ,respectively, each total rate was very significantly higher than stage I and stage II. Conclusion Combined use of CYFRA21-1, CA125 and CEA measurement may play a complementary role and evidently raise the detection rate of NSCLC in comparison with use of any single marker. In addition, the rate of positive findings was found to increase with development of the disease.